Tris Pharma

Tris Pharma, founded in 2000, is a privately held pharmaceutical company specializing in the development and commercialization of innovative drug delivery technologies. The firm maintains a robust portfolio of branded ADHD medications while simultaneously expanding its niche generics business. By leveraging proprietary technology platforms, Tris Pharma addresses complex therapeutic needs, focusing on patient-centric solutions within the specialty pharmaceutical and biopharmaceutical sectors. Their product pipeline includes advanced formulations such as suspensions and specialized tablets, designed to improve patient adherence and therapeutic outcomes in the competitive medical space.

Operating with 500-1,000 employees across 2 locations, the company emphasizes research-driven innovation and operational excellence. Meet Tris Pharma's team to understand the leadership and technical expertise driving their commercial-stage operations. The organization integrates advanced manufacturing capabilities with a commitment to high-quality medical therapy, positioning itself as a significant player in the healthcare landscape. Their internal structure supports a wide range of functions, from engineering and technical development to sales and operations, ensuring that their drug delivery technology remains at the forefront of the industry.

With annual revenue reaching $90.0M, Tris Pharma demonstrates consistent growth in the specialty drug market. The company actively pursues development and licensing partnerships to enhance its market presence against competitors like Alkermes and Alvogen. Explore financial highlights to review detailed metrics regarding their revenue performance and funding history, including recent debt financing initiatives that support their ongoing expansion and innovation-driven business model. This financial stability allows the firm to continue investing in complex drug delivery systems, maintaining a competitive edge in theView more...